RD Lawrence Lecture 2012 Assessing aetiology in diabetes: How C-peptide, CRP and fucosylation came to the party!

Diabetic Medicine

Volumn 30, Issue 3, 2013, Pages 260-266

  Owen, K R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; C REACTIVE PROTEIN; GLICLAZIDE; GLUCOKINASE; HEMOGLOBIN A1C; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA;

DELAYED DIAGNOSIS; DOWN REGULATION; FUCOSYLATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; LOW DRUG DOSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN EXPRESSION; REVIEW;

ADOLESCENT; ADULT; AGE OF ONSET; BIOLOGICAL MARKERS; C-PEPTIDE; C-REACTIVE PROTEIN; CHILD; DELAYED DIAGNOSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FUCOSE; GENETIC TESTING; GENOTYPE; GLUCOKINASE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; PATIENT SELECTION; YOUNG ADULT;

EID: 84874136002     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12038     Document Type: Review

References (38)

1. Molven A, Njolstad PR. Role of molecular genetics in transforming diagnosis of diabetes mellitus. Expert Rev Mol Diagn 2011; 11: 313-320.
2. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010; 53: 2504-2508.
3. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003; 362: 1275-1281.
4. Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 2009; 26: 437-441.
5. Pontoglio M, Prie D, Cheret C, Doyen A, Lero C, Froguel P et al. HNF1 alpha controls renal glucose reabsorption in mouse and man. Embo Reports 2000; 1: 359-365.
6. Pearson ER, Boj SF, Steele AM, Barrett T, Stals K, Shield JP et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med 2007; 4: e118.
7. Feigerlova E, Pruhova S, Dittertova L, Lebl J, Pinterova D, Kolostova K et al. Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents. Eur J Pediatr 2006; 165: 446-452.
8. Stride A, Vaxillaire M, Tuomi T, Barbetti F, Njolstad PR, Hansen T et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia 2002; 45: 427-435.
9. Steele A, Shields BM, Shepherd M, Ellard S, Colclough K, Hattersley AT. Microvascular complication risk in patients with 50 years of moderte hyperglycaemia: are target ranges for glycaemic control appropriate?. Diabet Med 2011; 28: 28.
10. Gill-Carey OJ, Shields B, Colclough K, Ellard S, Hattersley AT. Finding a glucokinase mutation alters treatment. Diabetic Medicine 2007; 24(Suppl1): 6 A20.
11. Murphy R, Turnbull DM, Walker M, Hattersley AT. Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation. Diabet Med 2008; 25: 383-399.
12. Parker VE, Savage DB, O'Rahilly S, Semple RK. Mechanistic insights into insulin resistance in the genetic era. Diabet Med 2011; 28: 1476-1486.
13. Ledermann HM. Is maturity onset diabetes at young age (MODY) more common in Europe than previously assumed? [letter] [see comments]. Lancet 1995; 345: 648.
14. Kropff J, Selwood MP, McCarthy MI, Farmer AJ, Owen KR. Prevalence of monogenic diabetes in young adults: a community-based, cross-sectional study in Oxfordshire, UK. Diabetologia 2011; 54: 1261-1263.
15. Eide SA, Raeder H, Johansson S, Midthjell K, Sovik O, Njolstad PR et al. Prevalence of HNF1A (MODY3) mutations in a Norwegian population (the HUNT2 Study). Diabet Med 2008; 25: 775-781.
16. Thanabalasingham G, Pal A, Farmer AJ, Ellard S, McCarthy MI, Owen KR. Extending criteria for genetic testing increases diagnosis of maturity-onset diabetes of the young. Diabetologia 2010; 53: S63.
17. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.. N Engl J Med 2000; 342: 381-389.
18. Tattersall RB, SS Fajans. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes 1975; 24: 44-53.
19. Bellanne-Chantelot C, Levy DJ, Carette C, Saint-Martin C, Riveline JP, Larger E et al. Clinical Characteristics and Diagnostic Criteria of Maturity-Onset Diabetes Of The Young (MODY) due to Molecular Anomalies of the HNF1A Gene. J Clin Endocrinol Metab 2011; 96: E1346-E1351.
20. Thanabalasingham G, Pal A, Selwood MP, Dudley C, Fisher K, Bingley PJ et al. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care 2012; 35: 1206-1212.
21. International Diabetes Federation Definition of the Metabolic Syndrome 2006. Available at http://www.idf.org/metabolic-syndrome Last accessed 10 September 2012.
22. Bingham C, Ellard S, Nicholls AJ, Pennock CA, Allen J, James AJ et al. The generalized aminoaciduria seen in patients with hepatocyte nuclear factor-1alpha mutations is a feature of all patients with diabetes and is associated with glucosuria. Diabetes 2001; 50: 2047-2052.
23. Gloyn AL, Faber JH, Malmodin D, Thanabalasingham G, Lam F, Ueland PM et al. Metabolic Profiling in Maturity-Onset Diabetes of the Young (MODY) and Young Onset Type 2 Diabetes Fails to Detect Robust Urinary Biomarkers. PLoS One 2012; 7: e40962.
24. Cervin C, Axler O, Holmkvist J, Almgren P, Rantala E, Tuomi T et al. An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA. J Intern Med 2010; 267: 316-321.
25. Richter S, Shih DQ, Pearson ER, Wolfrum C, Fajans SS, Hattersley AT et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003; 52: 2989-2995.
26. Mughal SA, Park R, Nowak N, Gloyn AL, Karpe F, Matile H, et al. Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes. Diabetic Medicine 2012; in press.
27. Skupien J, Kepka G, Gorczynska-Kosiorz S, Gebska A, Klupa T, Wanic K et al. Evaluation of Apolipoprotein M Serum Concentration as a Biomarker of HNF-1alpha MODY. Rev Diabet Stud 2007; 4: 231-235.
28. Reiner AP, Barber MJ, Guan Y, Ridker PM, Lange LA, Chasman DI et al. Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet 2008; 82: 1193-1201.
29. Ridker PM, Pare G, Parker A, Zee RY, Danik JS, Buring JE et al. Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet 2008; 82: 1185-1192.
30. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA: the journal of the American Medical Association 2009; 302: 37-48.
31. Toniatti C, Demartis A, Monaci P, Nicosia A, Ciliberto G. Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites. Embo J 1990; 9: 4467-4475.
32. Shih DQ, Bussen M, Sehayek E, Ananthanarayanan M, Shneider BL, Suchy FJ et al. Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 2001; 27: 375-382.
33. Owen KR, Thanabalasingham G, James TJ, Karpe F, Farmer AJ, McCarthy MI et al. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care 2010; 33: 1919-1924.
34. McDonald TJ, Shields BM, Lawry J, Owen KR, Gloyn AL, Ellard S et al. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. Diabetes Care 2011; 34: 1860-1862.
35. Thanabalasingham G, Shah N, Vaxillaire M, Hansen T, Tuomi T, Gasperikova D et al. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes. Diabetologia 2011; 54: 2801-2810.
36. Lauc G, Essafi A, Huffman JE, Hayward C, Knezevic A, Kattla JJ et al. Genomics meets glycomics-the first GWAS study of human N-Glycome identifies HNF1alpha as a master regulator of plasma protein fucosylation. PLoS Genet 2010; 6: e1001256.
37. Thanabalasingham G, Huffman J, Kattla J, Novokmet M, Rudan I, Gloyn A, et al. Mutations in HNF1A result in marked alterations of plasma glycan profile. Diabetes 2012; in press.
38. Shields BM, McDonald TJ, Ellard S, Campbell MJ, Hyde C, Hattersley AT. The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia 2012; 55: 1265-1272.